2022 World Conference on Lung Cancer (ePosters)-EP16.01-032. Guiding Monotherapy with Docetaxel or Atezolizumab via the Tumour Mutation Index in Non-small Cell Lung Cancer Patients

EP16.01-032. Guiding Monotherapy with Docetaxel or Atezolizumab via the Tumour Mutation Index in Non-small Cell Lung Cancer Patients

Back to course

Pdf Summary

Researchers from the Shanghai Chest Hospital in China have developed a model using circulating tumour DNA (ctDNA) sequencing to predict the response to monotherapy with docetaxel or atezolizumab in patients with non-small cell lung cancer (NSCLC). The study, which analysed data from the POPLAR and OAK trials, identified three biomarkers - blood tumour mutation burden (bTMB), sensitive blood tumour mutation burden (sbTMB), and unfavourable mutation score (UMS) - to develop the tumour mutation index (TMI) model.<br /><br />The TMI model was able to stratify responders from non-responders and showed that patients who responded to docetaxel had a median overall survival (OS) duration of 5.55 months longer than non-responders. Similarly, atezolizumab responders had a 10.21-month OS advantage over non-responders. The TMI model was effective in both the POPLAR and OAK cohorts and was able to identify additional responders when the cohorts were combined.<br /><br />The findings demonstrate that ctDNA sequencing can provide a simple and rapid method for tumour genomic profiling in NSCLC patients. The TMI model could be a valuable tool for screening responders to monotherapy with docetaxel or atezolizumab, providing potential personalized treatment options for patients.<br /><br />The study highlights the potential of ctDNA sequencing as a non-invasive alternative to tissue biopsy for determining the genomic profile of NSCLC. The TMI model could potentially be used in clinical practice to guide treatment decisions and improve outcomes for patients with NSCLC. Further research and validation studies are needed to confirm the effectiveness of the TMI model in a larger patient population.

Asset Subtitle

Baohui Han

Meta Tag

Speaker Baohui Han

Topic Tumour Biology and Biomarkers - Immune Biology & Immunotherapy

Keywords

Shanghai Chest Hospital

ctDNA sequencing

monotherapy

docetaxel

atezolizumab

non-small cell lung cancer

TMI model

tumour genomic profiling

personalized treatment options

non-invasive alternative